Introduction
Antibiotic use is widely perceived to be high in the neonatal intensive care unit (NICU) but few studies have systematically examined its scope and purpose. 1, 2 This study addresses questions generated in a state-wide collaborative of California's Regional NICUs seeking to decrease healthcare-associated infections (HAI). 3 Its members questioned how the rate of presumed infection (PI) in NICUs, as inferred from antibiotic use measures, compared with proven central line-associated blood stream infection (CLABSI) or blood stream infection (BSI) rates, the customary metrics of NICUacquired infection. Although intuitively it was recognized that there might be large rate differences between these events, this is the first study in decades to examine total NICU antibiotic use. 4 Our findings, an exploratory analysis of a convenience sample, highlight how surveillance definitions of neonatal infection may underestimate its occurrence and behavioral definitions that is, measures of antibiotic use, may variably overestimate its occurrence. In the absence of more sensitive and specific tests for the presence of infection, we propose to term the middle ground between 'possible' and 'proven' infections as 'presumed' infections. Presumed infections share the characteristics of clinically worrisome signs and situations of both possible and proven infections, but, like 'possible' infections, are without positive sterile site cultures, and like 'proven' infections, receive a therapeutic antibiotic course (AC) (defined in this study as X5 d). Not withstanding the fact that PIs do not meet surveillance quality criteria for infection, they represent a heretofore poorly described complex of events, which either from the provider's or parent's perspective, are perceived as neonatal illness requiring treatment.
The goals of this report are to share our observations on how two sets of neonatologists use antibiotics for perceived infection, to test whether the use of antibiotics for PIs approximates that for proven infections, to stimulate others to consider, examine and refine measures of antibiotic use so as to better understand variations in antibiotic use, and to stimulate efforts to develop better testing and understanding of the presumed, but not proven, infected neonate.
Methods
Two NICUs (see Supplementary Table 1 : NICU Description) analyzed consecutive admissions for 3 (NICU#1) or 6 months (NICU#2) from 1 January 2008 until discharge. Pharmacy records and patient charts were reviewed for the following data: Line days (LD) and CLABSI events, noted using the current CDC definitions. 5 A BSI was noted, if a positive blood culture was associated with antibiotic treatment lasting X5 days. Patient days (PDs) and antibiotic use were recorded as follows: an antibiotic day (AD) was defined as a calendar day, in which at least one intravenous antimicrobial (including antifungals, but not antivirals) was given. An AC consisted of one or more uninterrupted AD. ACs were classified as perinatal (P) or neonatal (N), if started p3 d or X4 d post birth, respectively. Neonatal courses were divided according to indication for treatment as rule-out sepsis or PI, if treated for p4 d or X5 d, respectively. Because an AD was based on any antibiotic dose given in a calendar day, 4 days were chosen to capture the conventional 72-h courses that could overlap any 4 calendar days. Note was also made, if there was at least one antibiotic change during the PI courses. Other neonatal courses were: peri-operative prophylaxis (Periop), CLABSI, BSI, other positive sterile site culture and local infection. ACs and ADs were grouped into three categories by inferred clinical judgment of infection certainty:
1. Potential infection: empirical courses intended to treat those perceived at risk to be or become infected based on exposure to procedures or surgery (termed colloquially as 'at risk for sepsis'). This category also included patients in whom the clinician found minimal, short-term symptoms but no objective findings for infection, and discontinued treatment within 4 days. This category included both Periop and rule-out sepsis courses. 2. Presumed infection: courses lasting X5 d intended to treat infections where findings (not collected in our data set), such as abnormal white blood cell counts, an abnormal immature/ total neutrophil ratio, serial C-reactive protein. radiographic findings and/or changes in the patient physical examination, persuaded the physicians to continue antibiotic without a positive sterile site culture or an identified local infection. This category (also termed colloquially as 'clinical sepsis') included PI with or without antibiotic change during the course (we inferred that an antibiotic change indicated more clinical certainty that an infection was indeed present). This category includes both ventilator-associated pneumonias, a neonatal diagnosis often described as difficult to make, 6 and episodes of abdominal dysfunction, the disease spectrum of which varies from feeding intolerance to necrotizing enterocolitis unassociated with a positive sterile site culture. [7] [8] [9] 3. Proven infection: courses intended to treat infections associated with positive cultures from blood (CLABSI/BSI) or other sterile sites (cerebrospinal fluid, peritoneum, abscess, pleura, etc), or local infections with specific diagnoses such as cellulitis, thrombophlebitis, etc). Data on urinary tract infections defined by positive culture obtained by catheter or bladder aspiration were also collected, but listed separately as their classification remains controversial. 10 
Analysis
We hypothesized that proven bacterial/fungal neonatal infections were no more frequent than antibiotic treatment courses for PIs, in keeping with a priori expert opinions that blood culture sensitivity in the neonate is 'only 50-80% at best'. 8, 11 Rates (events per total PDs) were calculated for both total ACs and ADs associated with each of the three clinical judgment categories. Yates corrected w 2 -tests and odd ratios were calculated using the OpenEpi program (Version 2). 12 Significance was accepted, if the P-value was p0.05. Both collaborating hospital's Institutional Review Boards approved this study by expedited review.
Results
The two NICUs' characteristics, shown in Supplementary Table 1, indicate that both are very large units serving complex patient populations, both referred before and after delivery. Their total NICU admissions and very-low birth weight admissions were nearly identical in 2008. Bed numbers and admission volumes exceed the 75th percentiles for units reported in VON's Annual VLBW Summary by large margins (VON Annual VLBW Summary-2010, Burlington, VT, USA) Major surgical volume was large in both NICUs, but significantly different (OR 1.8 (CI 1.5-2.10)).
Antibiotic use was compared between the two NICUs (see Supplementary Table 2) . When judged by ACs initiated for proven infection, antibiotic use was not significantly different between the two NICUs (1.5 vs 1.3 AC/1000 PD, P ¼ 0.445), nor was it different when judged by ADs (19 vs 22 AD/1000 PD, P ¼ 0.084). They were also not statistically different using conventional HAI metrics: CLABSI events, whether measured per 1000 line days (0.3 CLABSI/ 1000 LD vs 1.6 CLABSI/1000 LD, P ¼ 0.12) or measured per 1000 PD (0.5 CLABSI/1000 PD vs 0.15 CLABSI/1000 PD, P ¼ 0.204). For this reason, we combined the data from both NICUs in one cohort, even though the data on antibiotic use for PI reflected clinically significant differences in initiating ACs and ADs for non-proven infections.
The combined cohort included 754 patients, 18 345 PD, 6637 line days. Total antibiotic use comprised 718 AC and 4553 AD. Supplementary Figure 1 shows the distribution of ADs by specific conventional treatment category.
Perinatal antibiotic use consisted of 510 ACs and 2767 ADs. As these courses were directed toward infection clinically perceived to be possible or present at delivery, they are not further considered in this report as they do not relate to assessing neonatal HAI prevention and treatment practices.
Supplementary Table 3 shows both the absolute numbers of ACs and ADs by specific infection categories, their rates expressed per 1000 PDs and the ratio of these rates relative to CLABSI events 1-11) . The conventional description of the CLABSI rate was 1.05/1000 LD.
The rate of ACs targeting PIs was 3.7 higher (OR 3.7 (CI 2.4-5.6), P<0.0001) than targeting proven infections, and the rate of ADs used to treat PIs was 2.4 times higher (OR 2.4 (CI 2.1-2.7), P<0.0001) than that used to treat proven infections (48.3 vs 20.6/1000 PD). The finding leads us to reject the hypothesis that the ratio of PI ACs to proven infection ACs is 1:1.
Discussion
Antibiotic-use measures, such as courses and days per 1000 PDs, may provide clinically significant data about the HAI burden in the NICU that supplements conventional metrics such as CLABSI and BSI rates. Their significance awaits our ability to describe the degree to which they indicate antibiotic overuse vs under-detection of antibiotic responsive disease. Our exploratory analyses indicate both strengths and weaknesses with these proposed metrics, just as there are also strengths and weaknesses with the conventional metrics.
We did not analyze perinatal antibiotic use further in recognition that much of early antibiotic use relates to maternal and perinatal events not affected by neonatal HAI prevention practices. However, the perinatal-related use is significant; it constitutes the largest portion of total neonatal antibiotic use, 71% of ACs and 61% of ADs in our sample. Surveillance definition based rates, which generate a lower limit estimate of acquired NICU infections, indicate that both centers exhibited indistinguishable and exemplary CLABSI and BSI rates by current standards. Their individual CLABSI rates, whether measured by events per central line days or PDs, and their proven infection rates, were not significantly different, leading to our pooling of these data. Their aggregate CLABSI rate was 1.05/1000 line days, and the BSI rate was 1.25/1000 PD; both rates are well within the range of recently reported rates. 13 As a consequence, both centers were similar in their antibiotic use to treat proven infection events.
We approached the data from a bedside clinician's perspective: describing the observed use of antibiotics in terms of inferred intent. Antibiotic use-measures, which generate an upper limit estimate of an NICU's acquired infections, showed significant differences between the two centers in measures related to PI management: a 1.6-fold difference in ACs initiated and a twofold difference in ADs administered for PI (see Supplementary Table 2 ). This expected variation falls within the range of a similar metric that examined perinatal rather than neonatal antibiotic use among 19 NICUs, in which perinatal antibiotic use for >5 days between NICUs varied threefold (27-85%). 14 Our study is limited in several ways. The data set is a convenience sample from two large NICUs rather than from a systematic sampling of a wider range of NICUs; this raises the question of its representativeness, notwithstanding the fact that both NICUs are considerably larger in size and volume than the upper quartile thresholds describing NICUs belonging to VON. Some event rates were relatively low, decreasing the power of statistical inference, but this is consistent with an exploratory analysis. Although it can be argued that the lack of clinical detail associated with each clinical treatment decision diminishes the study's ability to judge the factors leading to variable decision-making about antibiotic use, we would counter that as in the absence of reliable methods to decide which decisions are more appropriate than others, we have no means to adjudicate between observed differences in antibiotic use as yet. These challenges should be addressed in future studies.
Our data do point to very large and significant differences between antibiotic use deployed to treat CLABSIs and PIs. The ratio of these differences: for antibiotic courses 14:1 (CI 6.6-30) and for antibiotic days 8.8:1 (CI 7.1-11) suggest that: (1) the previously unquantitated magnitude of these differences is quite large, and certainly beyond the hypothesized 1:1 ratio stated for neonatal blood culture sensitivity; and (2) there is an urgent need to better understand the clinical ambiguity surrounding the treatment decisions that result from ambiguous clinical data ('noisy signals') being processed by clinicians according to variable, inconsistent rules (differing receiver operating characteristics).
Clinical decision methods may be applied to understand the physicians' assessments of patient findings and laboratory tests. In particular, we suggest that prospective studies of the events following antibiotic discontinuation should note cases of infection following shortly after antibiotic discontinuation (in our sample of 36 neonatal rule-out sepsis ACs, two infants were subsequently retreated for BSI 4 and 5 days respectively after the initial ACs were discontinued). The methods and data to compare the performance of these findings and tests are beyond this report's scope; although we foresee that such efforts can contribute additional understanding of their relationships. [15] [16] [17] [18] [19] [20] How reliable is the 'gold' standard? 'Proven' neonatal infectious events are dependent on blood-culture testing. Yet this 'gold standard' for diagnosing an infection is subject to many variables that affect its sensitivity and specificity. Buttery 21 noted the following factors affecting blood-culture test performance: skin preparation technique, choice of culture site, timing and number of culture(s), volume of blood drawn, ratio of blood to culture medium volume in the blood culture bottle and choice of blood culture bottle and system. Cornell reported how vascular access difficulties in infants less than 1 month of age may lead to submitting less than optimal volumes; blood culture yield rates were twice as high when at least 1 ml of blood was submitted (5.2 vs 2.2%). 22 In adult patients, the culture site (from the intravascular catheter vs from a peripheral venipuncture) affects both blood-culture sensitivity and specificity. 23 BSI detection is problematic because of the improbability of detecting low density bacteremia with small blood sample volumes. Kellog et al. 24 noted that 68% of 34 septic infants less than 2 months of age grew less than 10 cfu ml À1 .Schelonka et al. 25 investigated in vitro sensitivity of the BacT/Alert blood culture system (bioMerieux, Durham, NC) with four neonatal organisms, as the inoculum density increased from 1 to 4 cfu ml À1 , the probability of detecting one or more organisms in 1.0 ml samples increased from 0.63 to 0.98. Isaacman et al. 26 studied pediatric patients in whom two blood cultures were drawn (one of 2 ml and the other of 9.5 ml), with the larger aliquot then divided into 6 and 2 ml specimens. Their larger sample's sensitivity was 83%, higher than any individually smaller sample (60%) or combination of two smaller samples (73%), an effect also noted in adult patients. 27 Randolph et al. 8 concluded that baseline blood culture sensitivity is not accurately known, but may be lower than 70%, and in premature neonates, when volumes of 1 ml of blood are drawn, the sensitivity may be even lower. Gerdes 11 similarly concluded that blood culture sensitivity is 'only 50-80% at best,' based on low blood-culture yield associated with clinically significant pulmonary infections and studies indicating that only 80% of autopsy proven infections are diagnosed with premortem blood cultures. 28, 29 Unfortunately, the potential for molecular diagnostic techniques to produce both speedier and better performing tests for bacteremia has yet to be realized. 30 CLABSI enumeration has been used as one HAI surveillance gold standard because of its alleged objective nature. However, recent validation studies of CLABSI enumeration in adults by McBryde et al. 31 and Lin et al. 32 suggest significant operator variance. In that infection preventionists also adjudicate all neonatal events as well, it can be anticipated that similar results may be found in future validation studies of neonatal BSI events. This notion is strengthened by the reported poor agreement (71% (k ¼ 0.32)), even among three expert physicians in retrospectively classifying suspected neonatal and pediatric infections. 33 In summary, these studies indicate how reported CLABSI and BSI rates may underestimate the real neonatal infection burden.
How reliable is clinical judgment?
Fischer et al. 34 prospectively compared clinical judgments about treatment of serious pediatric infectious events with subsequent blood culture results. The physicians' median probability estimate of infection increased from 0% at baseline to 2% on the day preceding antibiotic therapy and then to 20% on the day that antibiotic treatment was initiated (P<0.001). For neonates, these physicians showed a good ability to predict blood culture-positive sepsis, after adjusting for age and study unit (ROC, 0.77; 95%CI, 0.70-0.83; P ¼ 0.28), that is, the 10.7% observed rate of positive blood cultures was not significantly different from the 15% predicted rate.
Okascharoen et al. 35 described how clinical judgment might be improved by structuring the assessment of clinical signs and tests related to the suspicion of late-onset sepsis. Sarkar et al. 36 and Modi et al. 37 have separately assessed the association of positive blood cultures and prospectively collected standardized sets of neonatal clinical signs and tests. Whether, and how, to improve neonatologists' treatment decisions, is a question that merits further investigation.
From the quality improvement specialist's perspective, these 'real' clinical events should be included in the enumeration of each NICU's-perceived infection burden. The challenge is to understand the totality of interactions between the frequency of HAI events, the sensitivity and specificity of clinical assessments, the efficacy of differing treatment thresholds, especially as they reflect herd effects on antibiotic resistance 13 and the utility of QI interventions to alter these events. Processes to be addressed might include: blood culture technique and systems, timing and techniques for measuring inflammatory markers and clinical skills in assessing 'suspicious' infants. Prospective studies of decision-making may enable developing evidence-based guidelines to reduce variability in clinical judgment, especially with regard to halting antibiotic courses too early or continuing them too long. From this perspective, case-mix adjusted antibiotic-use measures may be useful both to guide QI efforts relating to reducing NICU HAI, as well as aiding antibiotic stewardship.
Conclusion
CLABSI rates, used currently to assess HAI prevention efforts, reflect only a small fraction of treated neonatal infections. In our study, antibiotic use, whether measured by courses or days, was 9-14 fold higher for indications other than CLABSIs. Although these two Level IIIC 38 NICUs showed a nearly twofold difference in antibiotic use for PI, this difference is small compared with the observed differences between antibiotic use targeting CLABSIs and PIs. Thus, solely tracking CLABSI rates may miss much of the clinicians' perception of NICU acquired infection. We propose that AC and AD metrics be further studied for their ability to complement CLABSI rates as means to assess the NICU's HAI burden.
